Responses of Solid Organ Transplant Recipients to COVID-19 Vaccination

In a phase 3b trial of the mRNA-1273 vaccine in SOTRs, three initial doses followed by a booster increased neutralizing antibody titers and reduced cases of COVID-19.

Although vaccination of solid organ transplant recipients (SOTRs) is an important tool in preventing severe COVID-19 infection, these individuals often have suboptimal responses to immunization. As the best vaccination schedule has not yet been established, a three-dose primary series followed by a subsequent booster is currently recommended. To examine this issue further, investigators at Moderna conducted an open-label phase 3b post-marketing study of the mRNA-1273 vaccine to assess its safety and immunogenicity in 214 SOTRs (137 kidney recipients and 77 liver recipients) and 20 immunocompetent participants; enrollment began in April of 2021.

Twenty-eight days after the three-dose primary series, SARS-CoV-2 neutralizing antibody geometric …

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Responses of Solid Organ Transplant Recipients to COVID-19 Vaccination

Topics

Reviewing Author